

IN THE CLAIMS:

1-55. (Canceled)

56. (Currently amended) An isolated antibody, or a fragment or derivative thereof, which specifically binds to an epitope present within amino acids 175-536 of a human ECRTP/DEP-1 polypeptide, in a diluent or excipient pharmaceutically acceptable in humans.

57. (Currently amended) The isolated antibody fragment of claim 56, wherein the antibody fragment is selected from the group consisting of an Fab fragment, an Fab' fragment, an F(ab')<sub>2</sub> fragment, an F(v) fragment, and an single chain fragment variable (scFv) fragment.

58. (Currently amended) The isolated antibody of claim 56, which is a monoclonal antibody, or a fragment or derivative thereof.

59. (Currently amended) The isolated antibody of claim 58, which is monoclonal antibody ECRTPAb-1, having a molecular weight of about 150 kDa and which specifically binds to an epitope present within amino acids 175-536 of a human ECRTP/DEP-1 polypeptide.

60. (Currently amended) The isolated antibody of claim 58, wherein the antibody is human or humanized.

61. (Currently amended) The isolated antibody of claim 60, which binds an eight amino acid epitope having the sequence QSRDTEVL (SEQ ID NO: 1).

62. (Canceled).

63. (Currently amended) An isolated antibody, or a fragment or derivative thereof, which specifically binds to an epitope of an ECRTP/DEP-1 polypeptide extracellular domain, the epitope comprising the sequence QSRDTEVL (SEQ ID NO: 1).

64. (Currently amended) The isolated antibody fragment of claim 63, wherein the antibody fragment is selected from the group consisting of an Fab fragment, an Fab' fragment, an F(ab')<sub>2</sub> fragment, an F(v) fragment, and an single chain fragment variable (scFv) fragment.

65. (Currently amended) The isolated antibody of claim 63, which is a monoclonal antibody or a fragment or derivative thereof.

66. (Currently amended) The isolated antibody of claim 65, wherein the antibody is human or humanized.

67. (Currently amended) The isolated antibody of claim 63, in a pharmaceutically acceptable diluent or excipient.

68. (Currently amended) An isolated antibody, or a fragment or derivative thereof, which specifically binds an extracellular domain of an ECRTP/DEP-1 polypeptide and wherein the antibody, fragment, or derivative thereof has activity in modulating angiogenesis, in a diluent or excipient pharmaceutically acceptable in humans.

69. (Currently amended) The isolated antibody of claim 68, or a fragment or derivative thereof, wherein the antibody, fragment, or derivative thereof has activity in modulating angiogenesis in an assay selected from the group consisting of a planar endothelial migration assay, an *in situ* transfection assay for migration, a cornea pocket angiogenesis assay, a chick chorioallantoic membrane assay, a proliferation assay, and an endothelial wound closure assay.

70. (Currently amended) The isolated antibody fragment of claim 68, wherein the antibody fragment is selected from the group consisting of an Fab fragment, an Fab' fragment, an F(ab')<sub>2</sub> fragment, an F(v) fragment, and an single chain fragment variable (scFv) fragment.

71. (Currently amended) The isolated antibody of claim 68, which is a monoclonal antibody, or a fragment or derivative thereof.

72. (Currently amended) The isolated antibody of claim 71, wherein the antibody is human or humanized.

73. (Currently amended) The isolated antibody of claim 68, in a pharmaceutically acceptable diluent or excipient pharmaceutically acceptable in humans.

74. (Currently amended) The isolated antibody of claim 68, further having a binding specificity of a monoclonal antibody produced by a hybridoma cell line having American Type Culture Collection (ATCC) accession number HB12570.

75. (Currently amended) The isolated antibody of claim 68, wherein the monoclonal antibody is a monoclonal antibody produced by a hybridoma cell line having American Type Culture Collection (ATCC) accession number HB12570.

76. (Currently amended) An isolated antibody, or a fragment or derivative thereof, which specifically binds an epitope present within amino acids 175-536 of a human ECRTP/DEP-1 polypeptide, and wherein the antibody, fragment, or derivative thereof has activity in modulating angiogenesis, in a diluent or excipient pharmaceutically acceptable in humans.

77. (Currently amended) The isolated antibody of claim 76, or a fragment or derivative thereof, wherein the antibody, fragment, or derivative thereof has activity in modulating angiogenesis in an assay selected from the group consisting of a planar endothelial migration assay, an *in situ* transfection assay for migration, a cornea pocket angiogenesis assay, a chick chorioallantoic membrane assay, a proliferation assay, and an endothelial wound closure assay.

78. (Currently amended) The isolated antibody fragment of claim 76, wherein the antibody fragment is selected from the group consisting of an Fab fragment, an Fab' fragment, an F(ab')<sub>2</sub> fragment, an F(v) fragment, and an single chain fragment variable (scFv) fragment.

79. (Currently amended) The isolated antibody of claim 76, which is a monoclonal antibody, or a fragment or derivative thereof.

80. (Currently amended) The isolated antibody of claim 79, which is monoclonal antibody ECRTPAb-1, having a molecular weight of about 150 kDa and which specifically binds to an epitope present within amino acids 175-536 of a human ECRTP/DEP-1 polypeptide.

81. (Currently amended) The isolated antibody of claim 79, wherein the antibody is human or humanized.

82. (Currently amended) The isolated antibody of claim 76, in a ~~pharmaceutically acceptable~~ diluent or excipient pharmaceutically acceptable in humans.

83. (Currently amended) An isolated antibody, or a fragment or derivative thereof, which specifically binds to an epitope of an ECRTP/DEP-1 polypeptide extracellular domain, the epitope comprising the sequence QSRDTEVL (SEQ ID NO: 1), wherein the antibody, fragment, or derivative thereof has activity in modulating angiogenesis.

84. (Currently amended) The isolated antibody of claim 83, or a fragment or derivative thereof, wherein the antibody, fragment, or derivative thereof has activity in modulating angiogenesis in an assay selected from the group consisting of a planar endothelial migration assay, an *in situ* transfection assay for migration, a cornea pocket angiogenesis assay, a chick chorioallantoic membrane assay, a proliferation assay, and an endothelial wound closure assay.

85. (Currently amended) The isolated antibody fragment of claim 83, wherein the antibody fragment is selected from the group consisting of an Fab fragment, an Fab' fragment, an F(ab')<sub>2</sub> fragment, an F(v) fragment, and an single chain fragment variable (scFv) fragment.

86. (Currently amended) The isolated antibody of claim 83, which is a monoclonal antibody or a fragment or derivative thereof.

87. (Currently amended) The isolated antibody of claim 86, wherein the antibody is human or humanized.

88. (Currently amended) The isolated antibody of claim 83, in a ~~pharmaceutically acceptable~~ diluent or excipient pharmaceutically acceptable in humans.

89. (Currently amended) An isolated antibody having a binding specificity of an antibody produced by a hybridoma cell line having American Type Culture Collection (ATCC) accession number HB12570.

Serial No.: 09/516,728

Please add the following new claims:

90. (New) The isolated antibody of claim 68, or a fragment or derivative thereof, wherein the activity in modulating angiogenesis is inhibition of angiogenesis.

91. (New) The isolated antibody of claim 76, or a fragment or derivative thereof, wherein the activity in modulating angiogenesis is inhibition of angiogenesis.

92. (New) The isolated antibody of claim 83, or a fragment or derivative thereof, wherein the activity in modulating angiogenesis is inhibition of angiogenesis.